The GLP-1 receptor agonist exenatide may be an alternative to insulin for the management of cystic fibrosis-related diabetes (CFRD), a pilot study carried out by endocrinologists in South Australia suggests. In a study involving six young people with CF, pancreatic exocrine insufficiency and impaired glucose tolerance (IGT), they found that a subcutaneous injection of exenatide ...
GLP-1 drug could be better alternative to insulin for CF-related diabetes
By Michael Woodhead
11 Oct 2018